MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
15-Dec-2008
- Germany
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Pluradent AG & Co KG - Offenbach, Germany
Go to page
Sacred_fig
Go to page
Worldwide cost for dementia $315 billion
Go to page
Talecris Continues Global Expansion into Europe - Talecris Biotherapeutics GmbH established as a wholly-owned sales and service organization to serve more than 15 European countries
Go to page
SPP100 (Tekturna/Rasilez) reduces left ventricular hypertrophy - Latest study reveals further potential benefits of renin inhibitor in heart disease
Go to page
Wittenfeld & Cornelius GbR - Bochum, Germany
Go to page
Scientists Most Value Sales Reps That Are Knowledgeable, Not Sales-Oriented
Go to page
Basilea's antibiotic BAL30072 shows activity against superbugs expressing the NDM-1 resistance factor
Go to page
Using nature as a model for low-friction bearings
Go to page
Scientists achieve first rewire of genetic switches
Go to page